Piscataway, NJ, November 10, 2022–Camber Pharmaceuticals is pleased to announce the addition of Pirfenidone Tablets to its current portfolio.
Pirfenidone Tablets are indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
Pirfenidone Tablets from Camber are available in two strengths:
- 267 mg in 3 pack/ 90 count bottles (270 count total)
- 801 mg strength in 90 count bottles
To find out more about Pirfenidone Tablets please visit www.camberpharma.com
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.
# # #
If you would like more information about this topic, please contact Megan Little at [email protected]
